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ABSTRACT  
Microscopic colitis (MC) is an inflammatory bowel disease (IBD) and a common cause of 
chronic non-bloody diarrhoea, especially in elderly women. There are two main subtypes, 
lymphocytic colitis (LC) and collagenous colitis (CC) which are clinically indistinguishable 
and can be separated only by their characteristic histopathological features. The colonoscopy 
is usually macroscopically normal although subtle mucosal changes have been reported. The 
aetiology of MC is unknown and the genetic factors are poorly investigated. 
This thesis aims to describe MC in a large urban cohort and compare LC and CC regarding 
clinical and endoscopic features, both at diagnosis and at follow-up (F-U), and to observe the 
occurrence of coeliac disease, ulcerative colitis (UC) and Crohn’s disease (CD). We also 
reported the histological change of the MC phenotype over time and patients’ MC medication 
at last F-U. Further, we tested immune-related genes, known to impact several autoimmune 
diseases, for their potential CC-predisposing role. Finally, this thesis aims to report on 
chromoendoscopic findings in MC. 
A retrospective study of 795 patients showed that the clinical features of LC (n=451) and CC 
(n=344) were similar, though watery diarrhoea occurred at a lower frequency in LC (43%) 
than CC (55%) as did nocturnal diarrhoea, LC (18%) and CC (28%). The mean age at 
diagnosis was lower in LC, at 59 years compared 63 years in CC. Subtle endoscopic mucosal 
findings were frequently reported at a higher rate in CC (37%) than LC (25%). Our study 
confirms MC’s strong association with coeliac disease, which occurred in 6% of the patients. 
UC and CD occurred in 2.1% of the patients. 
In the MC cohort, 687 patients had a clinical F-U after a mean time of 2.89 years at which 
64% were in clinical remission. The cumulative clinical remission was higher in LC. About 
half of the patients had received medical treatment for MC at last F-U and about a quarter of 
them were on steroids; both these parameters were lower in patients with LC. The mean time 
for the first F-U colonoscopy (n=187) was 3.33 years and the histological remission was 44% 
and the cumulative histologic remission was higher in LC. Histological change of phenotype 
over time was not uncommon and was observed in 12 % of the patients (10 CC to LC, 13 LC 
to CC). 
Three independent CC and control cohorts were genotyped with Immunochip and 42 markers 
gave rise to significant genome-wide associations signals, all within the HLA region of 
chromosome 6. The most pronounced risk effects were observed for 8.1 haplotype alleles 
including DQ2.5. The HLA genotype is associated with CC and indicates immune-driven 
pathogenesis. 
Previously, two case reports described that chromoendoscopy in CC patients showed uneven 
surface. We reported additional chromoendoscopic findings in 13 MC patients that showed 
continuous mucosal changes. Our study supports the fact that chromoendoscopy can reveal 
mucosal changes in MC and therefore might be diagnostically useful. 
LC and CC are similar but not identical, since LC has a milder clinical presentation and a 
better prognosis than CC. Conversions between subtypes and between MC and UC or CD 
exist. It is not uncommon with macroscopic changes of the colonic mucosa in patients with 
MC which are more manifest with chromoendoscopy. Specific HLA alleles are associated 
with CC, indicating an autoimmune role.  
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1   INTRODUCTION  
Microscopic colitis (MC) is an inflammatory bowel disease (IBD) clinically characterised by 
chronic non-bloody diarrhoea, predominantly presenting in female elderly patients. 
Macroscopically, the colonic mucosa has been described as normal or nearly normal, with 
characteristic histological findings differentiating between its two major subtypes, 
lymphocytic colitis (LC) and collagenous colitis (LC). The cause of MC is unknown and is 
most likely multifactorial. Budesonide is an effective treatment but the relapse rate is high 
after withdrawal. 
CC was first described by the Swedish pathologist Lindström in 1976 (1), the same year that 
Freeman et al. reported two patients suffering from the same condition (2). In 1989, Lazenby 
et al. (3) described LC and in 1993, a French and an American research group suggested the 
use of MC as an umbrella term covering any form of colitis with normal endoscopic and 
radiological examination characterised by histological changes (4, 5). 
1.1   EPIDEMIOLOGY  
MC is a common disease and is mainly reported in Europe and North America but it is seen 
worldwide (6-13). Epidemiological studies in Europe, the United States and Canada show its 
rising incidence over the past two decades (12, 14, 15) but a recent Swedish study shows 
stabilising incidence rate of 5/100 000 inhabitants for each subtype (16) which is at the same 
level as the pooled incidence rates from North American and European studies (17). A recent 
nationwide study in Denmark (2002-2011) reported an annual MC incidence of 24.7/100 000 
inhabitants in 2011, 9.8/100 000 for LC and 14.9/100 000 for CC (18) which aligns with a 
recent from United States study covering almost the same period (14). In the Danish study 
(18), there was almost a twofold increase over time in the number of endoscopies from which 
colon biopsies were taken, which partly explains the rising incidence - a result of increased 
awareness of MC; this is supported by another study (19). The prevalence of MC in Sweden 
is 123/100 000 (16) and 219/100 000 in United States (14) which is approaching the same 
prevalence as of classical IBD in Europe, 213/100 000 for Crohn’s disease (CD) and 294/100 
000 for ulcerative colitis (UC) (20). 
The prevalence of chronic diarrhoea is 4-5 % in Western populations (21). Patients with 
chronic non-bloody diarrhoea undergoing a colonoscopy are diagnosed with MC in 10-14% 
of cases and in about 20% of cases in males over 70 years of age and females over 50 years 
of ages (22, 23). 
MC is most seen in elderly individual but it can be diagnosed in patients of all ages including 
children (24-27). It has been reported that 25% of patients diagnosed with CC are younger 
than 45 years of age (28). The mean age at diagnosis is 61.1 ± 6.5 years, with no significant 
differences between the subtypes (29). Furthermore, MC is more common in females (16) 
and the female: male ratio is more pronounced in CC than LC, at  about 7:1 (7, 28) and 2-3:1 
(13, 30) respectively. 
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1.2     AETIOLOGY  AND  PATHOPHYSIOLOGY  
The aetiology of MC is unknown, but it is probably multifactorial. The prevailing theory is 
that it is a specific immune response to unknown luminal agents in genetically predisposed 
individuals with a disturbed barrier function which leads to uncontrolled inflammation in the 
colonic mucosa. The theory is based on the fact that MC is associated with autoimmune 
diseases and has familial clustering. The theory of luminal agents in the pathogenesis of MC 
is supported by the observation that faecal stream diversion results in regression of colonic 
inflammation which reappears after the reconstruction of bowel continuity in CC (31). 
Whether or not LC and CC are the same disease remains an unanswered question and a 
matter of debate (32-35). In addition, conversions between the subtypes have been reported 
(35, 36). In the following section, some proposed factors are discussed. 
1.2.1   Autoimmunity  
Concomitant autoimmune disorders are common in MC patients, 30-50% have at least one 
autoimmune disease (37), such as type 1 diabetes mellitus, thyroid disorders, rheumatoid 
arthritis or Sjögren’s syndrome. Coeliac disease is the most common concomitant 
autoimmune disease, seen in 2-20% MC patients (29). Furthermore, a United States study 
found that 4.3 % of a large coeliac disease patient cohort was diagnosed with MC (38). There 
have also been reports of concomitant or interchange between UC or Crohn’s disease and 
MC (39, 40). However, the number of cases is small and histological changes typical of UC 
and CD (Paneth cell metaplasia and crypt architectural distortion) are occasionally seen in 
MC (41). A diagnostic autoantibody has yet to be found. 
1.2.2   Genetic  factors  
Family occurrence has been described in MC (42-46). Studies have shown an association of 
MC with the HLA (HLA-DQ2), TNFa, IL-6 and serotonin transporter promoter gene 
polymorphisms as well as with allelic variation of the matrix metalloproteinase-9 (47-52). 
Coeliac disease is strongly associated with HLA-DQ2 (53) suggesting some similarities in 
pathogenesis. MC’s HLA association, the high occurrence of immune-mediated diseases and 
the response to corticosteroid treatment in MC suggest an autoimmunity (48). However, 
genetic MC studies are scarce and underpowered and large-scale genome-wide association 
studies are lacking. 
1.2.3   Drugs  
There are several reports of drug-induced MC (54, 55). NSAIDs, PPIs and SSRIs were 
identified as the three drugs with highest likelihood to cause MC (56, 57). A direct cause-and-
effect relationship has not been established for any of these drugs. Furthermore, most of the 
drugs that have been associated with MC are known to have diarrhoea as a side-effect (58) 
and therefore increase the likelihood for these patients to undergo endoscopy. However, after 
adjusting for more frequent endoscopies only the association between PPIs and CC and 
between SSRIs and LC remained significant (59). The pathophysiology can be explained by a 
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direct pharmacological effect on the colon, altered intestinal bacterial flora or idiosyncratic 
hypersensitivity reaction (60). 
1.2.4   Smoking  
A study by Vigren et al. showed that 37% of CC patients smoked, compared to 17% of 
controls. In younger individuals (16-44 years), 75% of CC patients were smokers versus 15% 
of controls. Active smokers develop the disease 10 years earlier than non-smokers (61). 
Further studies have confirmed that smoking is a risk factor for MC (62, 63). 
1.2.5   Bile  acid  malabsorption  
Patients with bile acid malabsorption (BAM) have diarrhoea. BAM has been diagnosed using 
SeHCAT in up to 60% of patients with LC and 44% of patients with CC (64, 65). 
Morphological changes in terminal ileum in MC such as villous atrophy, inflammation and 
collagen deposit have also been described in MC patients (34, 66). Similar to LC, colonic 
infusion of bile acids in animal models causes colitis (67). Bile acid binding treatment has 
been effective in CC, improving symptoms even in patients with normal SeHCAT tests (64, 
66). This might be due to that this treatment may binds other unknown luminal agents (68). 
Although bile acid binders can be clinically effective, they do not improve the histological 
changes in CC (69). 
1.2.6   Infections/Brainerd  diarrhoea  
Some MC patients have acute onset of symptoms similar to gastroenteritis and have been 
reported to respond to antibiotic therapy (28). Onset of MC after infections with Yersinia 
enterocolitica, Campylobacter jejuni or Clostridium difficile have occasionally been reported 
(70-72). A seasonal pattern of LC onset may support infectious origin (30). However, stool 
cultures are negative in most cases of MC with acute onset. Furthermore, LC resembles 
“Brainerd diarrhoea”, which is characterised by chronic acute onset watery diarrhoea with 
long duration and mucosal lymphocytosis in colonic biopsies. The cause is thought to be 
infectious and respond to antibiotics but no causative infectious agents have been identified 
(73, 74). 
1.2.7   Diarrhoea  mechanism  
CC patients were found to have abnormal epithelial barrier function and increased 
paracellular and transcellular mucosal permeability (75, 76). The precise mechanism of 
diarrhoea in MC is not clearly known. Burge et al. describe the triple mechanism of diarrhoea 
in CC: (I) malabsorption due to collagen bands and defective transporters, (II) secretory due 
to active chloride secretion and (III) leakage flow secondary to alterations to the epithelial 
barrier due to the down-regulation of epithelial tight junctions and passive leak of water and 
ions into the lumen (77). On the other hand fasting seems to decrease diarrhoea supporting an 
osmotic component (78). MC patients do not seem to have anal dysfunction or rectal 
hypersensitivity (79). 
 9 
 
1.2.8   Role  of  eosinophil  granulocytes/mast  cells  
Eosinophil granulocyte infiltrates are seen in CC patients and these cells are activated in 
active CC (80), and they are regarded as pro-inflammatory cells that can release cytotoxic 
proteins. In one study of 12 CC patients, two eosinophil-derived cytotoxic proteins were 
found in the faeces and both decreased after budesonide treatment (81). The mast cells are 
also present in CC patients (82). A case report of a patient with MC with increased mast cells 
in the lamina propria improved on antihistaminic therapy (83). Mast cells may also mediate 
abnormal collagen deposition (84) and moreover, patients with mastocytosis often have 
fibrosis (85). 
1.2.9   Abnormal  collagen  metabolism  
The production and deposition of basement membrane collagen is regulated by peri-cryptal 
fibroblasts which seem to be activated in CC leading to increased collagen production (86). 
However, one study that measured messenger RNA levels found no increase collagen 
production (87). The findings are contradictory and difficult to draw any conclusions from. 
Since similar alterations in peri-cryptal fibroblasts in CC have been documented in the 
fibrotic form of UC (88) it is suggested that these changes in the subepithelial collagen layer 
are secondary to inflammation rather than a primary pathogenic element. 
1.3     CLINICAL  FEATURES  
1.3.1   Symptoms  
The main symptom is chronic or recurrent watery non-bloody diarrhoea (89), and despite 
some patients’ severe diarrhoea, serious dehydration is rare. Nocturnal diarrhoea (up to 60%), 
diffuse abdominal pain (50%) moderate weight loss (up to 50%), fatigue (50-60%), faecal 
urgency (70%) and incontinence (40%) are often associated symptoms (37, 90, 91). Active 
MC may significantly impair patients’ quality of life and the burden seems to be caused by 
faecal consistency, rather than faecal frequency (92, 93). The onset of MC is often insidious 
but it can mimic a sudden onset of enteric infection (28). There is symptomatic overlap 
between MC and IBS-D (94), and up to 58% of MC patients met the IBS criteria in a recent 
prospective study (95). The histopathological assessment separates MC from for IBS with a 
predominance of diarrhoea, since the colonoscopy is usually macroscopically normal. The 
clinical symptoms of LC and CC are similar and cannot be separated on clinical grounds (33, 
91, 96), and the differentiation is based on the histopathological features. It is not entirely 
clear whether LC and CC are one or two diseases. There are only a few comparative studies 
on both subtypes in the same population and most have been based on small sample sizes. 
1.3.2   Diagnosis  
Routine laboratory test are non-diagnostic and pathogenic microorganisms are generally not 
found in stool analyses. Faecal calprotectin does not appear to be useful in MC and research 
has been conducted for alternative biomarkers such as faecal eosinophil protein X, faecal 
eosinophil cationic protein and secretoneurin (81, 97). 
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MC diagnosis is based on histopathological examination of mucosal biopsies taken at 
colonoscopy in combination with patient’s clinical history of non-bloody chronic diarrhoea 
(98). Colonoscopy with random biopsies is required from the entire colon and rectum 
examined separately, as this allows the pathologist to know the origin of the biopsies. There 
are contradictory data about its topographical distribution, but it is generally accepted that the 
prevalence of microscopic findings of MC are highest in the right and transverse colon (37). 
Microscopic changes can be patchily distributed in MC (99) and the presence of 
inflammatory cells in normal colonic mucosa is more prominent in the right colon (100). MC 
is characterised by macroscopically normal colonic mucosa, or nearly normal with subtle 
mucosal findings such as erythema, oedema or abnormal vessel patterns (28, 30, 101). Even 
mucosal tears can be seen at colonoscopy in MC patients (102-106). 
The histology is also necessary to differentiate between the two major subtypes, LC and CC. 
The characteristic histopathological features of LC include an increased number of 
intraepithelial lymphocytes (≥ 20 lymphocytes per 100 surface epithelial cells) in the colonic 
mucosa, mixed inflammation in the lamina propria with or without surface epithelial damage, 
and a subepithelial collagen layer <10 µm thick (107). The characteristic histopathological 
features of CC are a thickened subepithelial collagen layer (≥10 µm) in the colonic mucosa, 
mixed inflammation in the lamina propria with or without surface epithelial damage and 
intraepithelial lymphocyte infiltration (107). 
Two case reports described chromoendoscopic findings in CC patients that showed uneven 
surfaces (108, 109). If further studies can confirm that macroscopic lesions could be more 
pronounced by using indigo carmine staining, targeted biopsies may be possible. 
1.3.3   Treatment  
Therapy primarily aims to achieve and maintain clinical remission and improve patient’s 
quality of life since no curative treatment for MC exists. 
Concomitant BAM and coeliac disease should be considered in MC patients, but so should 
smoking cessation and withdrawal from drugs that may induce diarrhoea. 
Budesonide is the best-studied MC treatment, having been investigated in three randomised 
placebo-controlled induction studies in CC patients (110-112) and two in LC patients (113, 
114), which were confirmed by Cochrane meta-analysis (115). In summary, budesonide was 
superior to placebos for inducing clinical remission in about 80% of MC cases; in fact, it may 
even be better than prednisolone (116) and has fewer side-effects. There is a high risk of 
relapse after budesonide cessation (60-80%) (110-112). Three randomised placebo-
controlled studies showed that low-dose budesonide (6-4.5 mg) for six to twelve months can 
maintain clinical remission in the majority of CC patients (117-119). After ceasing 
budesonide maintenance therapy, there was no difference between budesonide and placebo in 
the median time to relapse (117). 
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Budesonide is recommended as a first treatment option for inducing and maintaining clinical 
remission, and the dose should be tapered to a minimum. Other treatment options are poorly 
investigated, though antidiarrheal medication and cholestyramine can be effective in patients 
with mild symptoms. If budesonide treatment is not sufficient, MC should be reconfirmed. 
Patients intolerant of or not responding to budesonide are a clinical challenge. In steroid-
dependent or refractory patients, thiopurines may be effective as a maintenance therapy 
(120), and mercaptopurine seems better tolerated than azathioprine (121). Anti-TNF drugs 
have been tested in a few patients who are refractory to budesonide and immunomodulators 
(122-124) and suggest that anti-TNF drugs could be an alternative to colectomy, which is the 
last resort in patients who are refractory to medical treatment. 
1.3.4   Clinical  course  and  prognosis  
The information on MC’s natural course is limited and it often dates back to the time before 
budesonide treatment was available. MC has variable manifestations, from a single episode 
lasting a few months to persisting episodes or alternations between activity and remission. 
Two relatively recent studies show that most patients remain symptom-free or suffer only 
sporadic symptoms (125, 126). It is suggested that LC has a milder course than CC and a 
greater tendency towards spontaneous remission (127). Placebo response rates of 48% and 
12% were reported in LC and CC patients (113), respectively. In LC patients, diarrhoea 
resolution and histology normalisation were described in 80% of the patients (128). In 
another study, LC was manifested as a single episode in 63 % of cases (22).  
CC patients in remission (without diarrhoea) complain about abdominal pain more often 
compared to matched controls (93), suggesting that IBS like symptoms may be secondary to 
residual or past inflammation in the mucosa as seen in quiescent IBD (129). 
MC is a benign disorder but there have been reports of both spontaneous and post-
colonoscopy colon perforations that may be related to the presence of mucosal tears seen at 
colonoscopy (130) and this in turn reflecting NSAIDs use (131). Unlike other IBD forms, 
there is no evidence that MC is associated with increased risk of colonic cancer and therefore 
there is no need for screening colonoscopies (132, 133). Recent studies reported even smaller 
numbers of colonic polyps in MC patients compared to subjects with normal colon (134), 
even when including any history of adenoma and adenocarcinoma in earlier colonoscopies 
(133). Conversions between the subtypes have been observed over time (135-138), but it is 
unclear whether LC and CC are two separate entities or whether the two subtypes are one 
single disease. This issue is still a matter of debate (32-35). However, clinical practice 
management today is not influenced by the subtype. 
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2   AIMS  
1. To clarify if there are any differences between LC and CC with regard to the demographic 
data and the clinical, endoscopic and histopathological features, both at onset and at follow-
up, in a large, well-defined urban cohort. 
2. To identify any associations between MC and coeliac disease, UC and CD, and to observe 
if any conversions between the subtypes occur over time. 
3. To clarify the association between immune-related genes and CC. 
4. To evaluate whether MC can be diagnosed macroscopically using chromoendoscopy. 
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3   PATIENTS  AND  METHODS  
The LC and CC diagnoses were based on histopathological criteria in paper I and II whereas 
in paper III and IV the diagnoses were based on clinical and histopathological criteria and the 
clinical symptoms lasted at least three weeks. 
The histopathology criteria in LC patients included an increased number of intraepithelial 
lymphocytes (≥ 20 lymphocytes per 100 surface epithelial cells) in the colonic mucosa; 
mixed inflammation in the lamina propria, with or without surface epithelial damage; and a 
subepithelial collagen layer <10 µm thick. The CC histopathology included a thickened 
subepithelial collagen layer (≥10 µm) in the colonic mucosa and mixed inflammation in the 
lamina propria, with or without surface epithelial damage. 
3.1   PATIENTS  AND  CONTROLS  
3.1.1   Paper  I  and  II    
All patients (n=818) diagnosed with MC at Karolinska University Hospital and 
Sophiahemmet Hospital in Stockholm, Sweden, from 1 January 1980 to 31 May 2010 were 
identified. Ten cases with MC were not subtyped and were thus re-examined by a 
pathologist; seven of these were CC cases, two were LC cases, and one did not fulfil the 
criteria of MC and was excluded. All histological reports of the LC patients were re-evaluated 
and 22 patients were then excluded, as they did not fulfil the histological criteria of LC. Thus, 
795 patients were considered for this study. 
A validation of the histological diagnosis of MC showed an accuracy of 92%. All clinical 
data were evaluated retrospectively. We reviewed medical charts and recorded demographic 
data, as well as clinical and endoscopic features, including the occurrence of coeliac disease, 
UC and CD. Twenty patients with IBD were identified. After re-evaluating the endoscopic 
and histopathological reports, three patients with previous IBD diagnoses were excluded, as 
they did not fulfil the IBD criteria. The date of diagnosis was defined as the year and month 
when MC was confirmed histologically. 
As a control colorectal neoplasia population, we considered 745 individuals in the normal 
population, aged 19-70 years who were randomly invited to undergo a colonoscopy in 
Stockholm County as part of a study of Forsberg et al. (139). 
The follow-up study reported that 687 of the 795 individuals underwent a clinical follow-up 
during the study period, which ranged between 1980-2010. A total of 108 patients with MC 
had only an index visit and were not included. All clinical, endoscopic and histological data 
were evaluated retrospectively by reviewing medical charts. 
3.1.2   Paper  III  
Patients diagnosed with CC (n=321) were recruited at gastroenterology clinics in Hamburg, 
Germany (112, 140) and Stockholm, Malmö and Linköping in Sweden. Ninety-one German 
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and 163 Swedish patients were included in the discovery analyses, and 67 Swedish patients 
were included in the replication analyses. Exclusion criteria included history of IBD, coeliac 
disease, clinical/endoscopic signs of gastrointestinal infection, ischemic colitis or neoplastic 
disease. A diagnosis of coeliac disease was further ruled out in the majority of patients by 
anti-tissue transglutaminase serology. 
For the controls, we used data from three sets of controls representative of the German and 
Swedish general populations. German PopGen discovery controls (n=2018) were from a 
community-based sample, recruited through population registries and the University Hospital 
Schleswig-Holstein, Campus Kiel, blood bank (141). The Swedish discovery controls 
(n=2046) were healthy individuals from the Epidemiological Investigation of Rheumatoid 
Arthritis (EIRA) (142). The Swedish replication controls (n=330) were from study PopCol’s 
population-based colonoscopy study, which included 745 individuals (143). Written informed 
consent was obtained from all individuals included in the studies. 
3.1.3     Paper  IV  
Since 2007, endoscopists at Karolinska University Hospital have used chromoendoscopy in 
patients with chronic diarrhoea. Between 2007 and 2010, 13 patients with chronic diarrhoea 
and abnormal chromoendoscopic findings were identified including three men and 10 
women; 10 patients had CC and three had LC. Eight of the 13 patients had been previously 
diagnosed with MC (n=8), and had undergone a new colonoscopy due to recurrent diarrhoea. 
3.2   GENOTYPING  AND  QUALITY  CONTROL  
Genotyping with Immunochip beadarrays was carried out at the Institute of Clinical 
Molecular Biology genotyping facility in Kiel and the Genome Institute of Singapore. Signal 
intensity value data for all cases and controls were retrieved and combined at the Institute of 
Clinical Molecular Biology genotyping facility in Kiel for genotype clustering and calling, 
using the optiCall algorithm. After quality control (QC) measures were applied, 4216 
individuals and 110 634 Immunochip markers common to the Swedish and German data sets 
remained and were included in the combined analysis of the discovery cohorts. Upon 
association testing, the individual genotype raw intensity (cluster) plots were manually 
inspected for all markers showing suggestive association signals with p<1×10−5 (n=207) and 
poorly clustering SNPs were removed from subsequent analyses (n=19). The rs2187668 
(DQ2.5) and rs7454108 (DQ8) markers were genotyped in the replication cohort (both cases 
and controls) with Tagman SNP Genotyping Assays according to the manufacturer 
instructions. 
3.3   CHROMOENDOSCOPY  
The colonoscopies were carried out by three well-trained endoscopists, who had each 
performed more than 2000 colonoscopies. The colonoscopes were equipped with high-
definition television and close focus, but not with high magnification. Chromoendoscopy 
with indigo carmine 0.2 – 0.5 % was used. The mucosa was judged normal if the 
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chromoendoscopy showed normal innominate grooves (144). The endoscopists noticed three 
abnormal macroscopic appearances after dying with indigo carmine; mosaic pattern, an 
uneven surface and a nodular surface. The chromoendoscopic appearance was categorised 
accordingly in consensus. 
3.4   STATISTICAL  ANALYSIS  
3.4.1   Paper  I  
The results are expressed as means and as proportions. Student’s t-tests were used to analyse 
unpaired parametric variables, and either the chi-squared method or Fisher’s exact test was 
used to compare categorical variables. All statistics were performed using the Prism and 
Statistica software. 
3.4.2   Paper  II  
Results are expressed as means, ranges and proportions. Histological and clinical remission at 
follow-up was analysed using Kaplan-Meier estimates, followed by comparing the curves 
using the log-rank test. Statistical significance was assumed by a p-value less than 0.05 (two-
tailed analysis). Chi-squared test was used to compare categorical variables. All statistics 
were performed using the Prism and Statistica software. 
3.4.3   Paper  III  
Quantile-quantile (q-q) plots were generated to highlight where the strong Immunochip 
association results came from. Case-control association testing was performed using logistic 
regression to adjust for age, sex and origin. HLA variants were imputed. In total, 100 imputed 
HLA alleles were tested through logistic regression analysis adjusting for age, sex and 
country of origin. Association testing versus replication controls was performed with 
age/gender-adjusted logistic regression using rs2187668 and rs7454108 Immunochip 
genotype data from the PopCol population-based cohort. Combined analyses of all data sets 
were run again with logistic regression adjusting for age, sex and origin. A forest plot of risk 
effects across CC cohorts was produced. The SNP risk effect concordance between 
IBD/CD/UC and CC were compared using SNP effect concordance analysis (SECA). We 
obtained IBD GWAS and Immunochip meta-analysis data from the IIBDGC 
(ibdgenetics.org) and used these as first input data-set. CC Immunochip summary results 
were used as the second input data-set. SECA then performed statistical tests to determine 
whether there is an excess of SNPs where the effect directions (OR) are concordant across 
data set 1 and data set 2. Fisher's exact statistical tests were performed and a p-value was 
calculated for the observed number of clusters with significant concordance across data-sets. 
3.4.4   Paper  IV  
The demographic data results are expressed as means, medians and ranges. The endoscopic 
and chromoendoscopic appearance results are expressed as categorical variables. 
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4   RESULTS  
4.1   PAPER  I  
4.1.1   Demographics  
A total of 795 patients with MC patients were included, 43% (n=344) CC patients and 57% 
(n=451) LC patients. Of these MC patients, 76% (n=601) were females (F:M ratio 3.1:1), 
including 79% (n=271, F:M ratio 3.7:1) CC patients and 73% (n=330, F:M ratio 2.7:1) of LC 
patients. In CC, the mean age at diagnosis was 63.2 years (range 17–97 years): 62.5 years for 
females and 66.0 years for males (p=0.07). In LC, the mean age at diagnosis was 59.2 years 
(range 13–95 years): 59.8 years for females and 57.7 years for males (p=0.26). Sixteen per 
cent of MC (n=130) patients were diagnosed before the age of 45; 11% of CC patients (n=38) 
and 20% of LC patients (n=92). Smoking habits were recorded in 230 patients in CC patients, 
including 33% current smokers and 24% former smokers. Among the 304 LC patients who 
recorded smoking habits, 32% were current smokers and 20% were former smokers. 
4.1.2   Clinical  features  
At onset, 94% of the MC patients had diarrhoea: information on stool frequency was 
available for 63% (n=472) of these patients. 
CC: Diarrhoea (97%) with watery consistency (55%), weight loss (38%) with a mean of 7.2 
kg, abdominal pain (28%), nocturnal diarrhoea (28%) and faecal urgency (23%), see Figure 
1. Stool frequency (n=224): 53% had four to nine stools per day, 34% had ten or more stools 
per day and 13% had three or less stools per day. 
LC: Diarrhoea (91%) with watery consistency (43%), weight loss (33%) with a mean of 5.9 
kg, abdominal pain (30%), faecal urgency (21%) and nocturnal diarrhoea (18%), see Figure 
1. Stool frequency (n=248): 52% had four to nine stools per day, 31% had ten or more stools 
per day and 16% had three or less stools per day. 
 
Figure 1. Symptoms at diagnosis. *p-value <0.05, **p-value <0.01. 
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4.1.3   Endoscopic  findings  
A complete colonoscopy was performed at diagnosis for 307 patients (89%) of CC patients 
and 403 patients (89%) in LC patients. At index colonoscopy, 37% of CC patients and 26% 
of LC patients showed subtle changes, such as erythema, oedema or abnormal vessel patterns. 
There were 14 adenomas found in 12 of the CC patients (3.5%) and 36 adenomas found in 30 
of the LC patients (6.7%). None of the MC patients had colorectal cancer at the time of the 
index colonoscopy. 
4.1.4   Coeliac  disease  and  inflammatory  bowel  disease  
Coeliac disease occurred in 6 % (n=48) and IBD occurred in 2.1% (n=17) of the MC patients. 
CC: Coeliac disease was present in 17 patients (4.9%), including 15 females and two males. 
Twelve patients had a prior diagnosis, one at the same time and four after CC diagnosis. IBD 
was present in eight patients (2.3%), all diagnosed prior to CC. Three females and three 
males were previously diagnosed with UC and in CD, both patients with prior diagnoses were 
females. 
LC: Coeliac disease was present in 31 patients (6.9%), including 20 females and 11 males. 
Twenty-two patients had a previous diagnosis, six at the same time and three after MC 
diagnosis. IBD was present in nine patients (2.0%), including seven diagnosed prior to LC 
diagnoses and two diagnosed after LC diagnoses, both had CD. Two females and two males 
were diagnosed with UC, and two females and three males were diagnosed with CD. 
4.1.5   Collagenous  colitis  versus  lymphocytic  colitis  
Significant differences were found between the two subtypes. The Age at diagnosis was 
significantly higher among CC patients (63 years) than LC patients (59 years) (p=0.005). 
Clinical symptoms were similar in both entities, but chronic diarrhoea was significantly more 
common in CC patients (97%) than LC patients (91%) (p=0.0012), as was watery diarrhoea 
(p=0.0014), nocturnal diarrhoea (p=0.002), and fever (p=0.042). Blood in the stool was 
significantly more common in LC patients (p=0.0029). Subtle mucosal findings at the index 
colonoscopy were significantly more frequent in CC patients (37%) than in LC patients 
(26%) (p=0.0011). 
4.2   PAPER  II  
4.2.1   Clinical  follow-­up  
Of the 795 MC patients, 108 had only a clinical index visit with no follow-up during the 
study period (63 LC patients and 45 CC patients). Eighty-six per cent (n=687) of the patients 
had at least one follow-up visit during the study period, including 86% (n=388) of LC 
patients and 87% (n=299) of CC patients. The mean time from diagnosis to last follow-up 
was 2.89 (0.01-23.87) years: 2.51 (0.01-18.65) years for LC patients and 3.39 (0.03-23.87) 
years for CC patients. Sixty-four per cent (n=441) were in clinical remission at last follow-up, 
including 66% (n=257) of LC and 62% (n=184) of CC patients (NS). The significant 
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difference between LC and CC in course over time is illustrated by the Kaplan-Meier survival 
curves (p=0.0013) in Figure 2. For seven patients there was no information about the clinical 
status at follow-up. 
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Figure 2. Kaplan-Meier curves show the difference in clinical remission between CC and LC 
patients at last of follow-up, p=0.0013. 
4.2.2   Medication  use  
Overall, 49 % (n=336) were on medical treatment for MC at last clinical follow-up (45% for 
LC (176/388) and 54% (160/299) for CC (p=0.0377)). Steroid use at follow-up was recorded 
for 24% (164/687) of MC patients, including 21% (81/388) of LC and 28% (83/299) of CC 
patients (p=0.0382). Other treatments such as anti-diarrhoeal agents and cholestyramine were 
used by 9% and 8 % respectively. Of those in remission, 47% (208/441) were on medication 
for MC, compared with 54% (128/239) of those who were not in clinical remission (NS). 
4.2.3   Endoscopic  follow-­up  
A total of 187 MC patients (100 LC, 87 CC) had at least one follow-up colonoscopy. In LC 
patients, 22% (100/451) had a follow-up colonoscopy, compared to 25% (87/344) CC 
patients. The mean time from index colonoscopy to first follow-up colonoscopy was 3.33 
(0.02-15.2) years: 3.17 (0.02-15.2) years for LC patients and 3.53 (0.08-13.1) years for CC 
patients. Endoscopic follow-up of those in clinical remission (n=52) was indicated by 
histological evaluation (n=17), unspecific gastrointestinal symptoms (constipation, rectal 
bleeding and abdominal pain) (n=13), polyp surveillance (n=3) and unknown (n=16). There 
were no colorectal cancer incidents reported at follow-up, though adenomas were found in 
5% (n=10). Subtle mucosal abnormalities, such as edema, erythema or abnormal vessel 
patterns were described in 30% (n=56) of MC patients, including 27% (n=27) of LC and 33% 
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(n=29) of CC patient colonoscopies. Thirty-nine per cent (n=22) of these patients, including 
48% (n=13) of LC and 31% (n=9) of CC patients, were in histological remission. 
Histological remission was recorded at the follow-up colonoscopy for 44% (82/187) of MC 
patients, including 52% (n=52) of LC and 34% of CC patients (n=30) (p=0.018). The 
cumulative LC and CC histological rates are illustrated in Figure 3 (p=0.0098). 
 
 
Figure 3. Kaplan-Meier curves show the differences in histological remission between CC 
and LC at the follow-up colonoscopy, p=0.0013. 
Although a substantial number of patients (n=23) in histological remission were not in 
clinical remission, the association between histological and clinical remission was high 
(p=0.0001). Patients in histological and clinical remission were significantly more steroid-
free compared to those only in clinical remission (p=0.0311). Ten per cent (n=19) of the MC 
patients changed histological phenotype between index colonoscopy and first endoscopic 
follow-up, including 11 LC to CC and 8 CC to LC cases. Out of these 19 patients, 12 were 
not in clinical remission, two were in clinical remission and five had unknown clinical status. 
Furthermore, one patient experienced a change histological phenotype from LC to UC and 
one had LC and Crohn’s ileitis concomitantly. A total of 44 patients underwent a second 
follow-up colonoscopy, and four more patients with a changed histological phenotype were 
recorded, including two LC to CC and two CC to LC cases: none of these had changed 
phenotype at the first follow-up colonoscopy. Thus, in total 12% (23/187) experienced a 
histological change of MC phenotype during follow-up. 
4.3   PAPER  III  
We genotyped 254 patients with CC from Sweden (n=163) and Germany (n=91), and 
compared their genotypes with Immunochip data from 2046 healthy Swedish controls from 
the EIRA study and 2018 healthy German controls from the PopGen cohort. 
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After quality control of genotype data, 110 634 Immunochip SNP markers and 4216 
individuals were included in the association tests performed with logistic regression adjusting 
for age, sex and origin. The analysis resulted in the identification of 188 markers with 
association p<1×10−5, which were all but one contained within the major histocompatibility 
complex (MHC) region on chromosome 6, see Figure 4. Forty-two markers gave rise to 
significant genome-wide (p<5×10−8) association signals, all contained within the HLA region 
on chromosome 6 (best p=4.2×10−10 for SNP rs4143332), see Figure 4. 
 
Figure 4. Manhattan plot showing –log 10 p values of association for all Immunochip single 
nucleotide polymorphism markers passing quality control and manual cluster inspection. 
Genome-wide and suggestive significance levels are indicated with red and blue lines, 
respectively. HLA, human leucocyte antigen. 
There were significant differences in age and sex distribution between cases and controls, but 
after two additional tests, a strong MHC association signal was again detected in both 
analyses. We imputed classical HLA alleles and conducted an association test; a multiple 
HLA variants showed a significant association with diverse effects on CC risk. The strongest 
signals were detected for six HLA alleles associated with increased risk for CC which are all 
known to be part of the 8.1 ancestral haplotype (145). We could further confirm the 
association signal to be dependent on the 8.1 haplotype. The DQ2.5 molecule is carried by 
the 8.1 haplotype and this molecule is also found in the majority of patients with coeliac 
disease (146). DQ2.5 was targeted and confirmed in the replication data-set showing a 
significant association with strong effect on CC risk (p=2.3×10−11; OR=2.06; 95% CI (1.67 to 
2.55) in the combined analysis). 
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We inspected CC Immunochip association signals in correspondence with DNA sequence 
variations known to impact IBD risk (>25 000 IBD risk SNPs). Concordant risk effects were 
significantly enriched in all three disease comparisons, namely IBD versus CC (p<0.001), CD 
versus CC (p<0.001) and UC versus CC (p<0.01), thus suggesting genetic overlap between 
CC and IBD at immune-related risk loci. We also looked at known non-HLA IBD risk loci 
(n=162), which could be done for 99 regions. Eight out these 99 loci showed associations 
with nominal significance in CC patients. 
4.4   PAPER  IV  
Thirteen patients with chronic diarrhoea and abnormal chromoendoscopic findings were 
identified, 10 women and three men with mean age of 64.9 years (median 62, range 35-90) 
and mean duration of symptoms of 53.9 months (range 1-156). Ten had CC and three had 
LC. Endoscopic findings without indigo carmine staining were patchy and were seen in 10 of 
the thirteen cases. Endoscopic findings included diminished vascular patterns, increased light 
reflection, and increased vascular patterns. Continuous mucosal abnormalities were found at 
colonoscopy after indigo carmine staining in all thirteen cases, namely the disappearance of 
innominate grooves or presence of innominate grooves with a nodular surface. A swollen 
mosaic pattern was seen in five CC cases and in all three LC cases. An uneven surface (a 
rough surface without apparent nodules) was seen in four CC cases, one CC case in remission 
and one of LC case. A nodular surface (nodules of 1 – 3 mm) was recorded in five CC cases, 
but in no LC cases. 
In one CC patient, chromoendoscopy showed an uneven surface; however, histopathological 
examination showed normal mucosa. 
In another CC patient, chromoendoscopy showed edematous mucosa with mosaic changes in 
the sigmoid colon, but no pathologic findings were recorded in that region. 
A third CC patient had a normal rectal mucosa appearance at chromoendoscopy but 
microscopic assessment showed a thick subepithelial collagenous band. 
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5   DISCUSSION  
Study I and II are descriptive studies of all patients diagnosed with MC from two hospitals, 
spanning a period of nearly 30 years. We used the same histological criteria used in earlier, 
well-known Swedish MC studies from Örebro (28, 30) so that we could compare our results. 
The histopathological criteria of MC were recently reviewed by an elaboration of the 
European Crohn’s and Colitis Organisation (ECCO) and the European Society of Pathology 
(ESP) (98), and the histological criteria we used are almost identical. 
We validated the histological diagnosis of MC early in the process. Since the study 
population was so large, we randomly selected 50 cases, of the first 198 MC cases gathered, 
for histological reassessment. The accuracy was high at 92%, and therefore we refrained from 
re-examining the whole study population. 
The strengths of these two studies are the large number of patients collected during 30 years 
and the geographic-restricted catchment area. The studies are retrospective and there was a 
large amount of missing data which we interpreted as no findings. This strategy may have 
underestimated the true frequency of, for example, symptoms and current medications 
presented at follow-up. The lack of information on prior colonoscopies may underestimated 
the true frequency of adenomas since polypectomies might have been performed before 
entering the study. Moreover, the therapy strategy for MC has changed during the study 
period in favour of Budesonide which could have an impact both on clinical and histological 
remission rates at follow-up. A number of patients (14%) did not have any clinical follow-up 
within the study period. This was due to several factors, such as follow-up contact first after 
the defined study period or geographic migration and may lead to an underestimation of the 
true frequency of clinical remission. There may also be a selection bias regarding the follow-
up colonoscopies, since not all patients did an endoscopic control, and patients who submitted 
to colonoscopy might have had more persistent symptoms. 
5.1   CLINICAL  AND  ENDOSCOPIC  FEATURES  
5.1.1   Demographics  
MC is often seen in elderly patients and the mean age of diagnosis of MC (61 years) was 
similar to earlier reports which also showed no significant differences between the subtypes 
(11, 147, 148). However, as other Swedish studies have reported (22, 30, 149), we could 
show significant differences with lower mean ages in LC patients (59 years) than CC patients 
(64 years) at diagnosis. This supports the theory that LC may be an early stage of CC (150, 
151). Old age is a risk factor for developing MC (16, 33, 152), but 16% of the patients in our 
study were <45 years of age at the time of diagnosis and in a previous study on CC this figure 
was 25% (28). MC has even found among children (24). Another risk factor for developing 
MC is smoking (62, 63) and the majority of our patients were smokers (54%), in accordance 
with pooled clinical studies analyses (33). 
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5.1.2   Symptoms  
One of the aims was to characterise the clinical features of MC, and therefore only 
histopathological criteria were used. This allowed us to analyse the whole spectrum of 
clinical symptoms in cases with histologically proven MC. In our study, 4%, including a 
majority of LC patients, had no diarrhoea, which is same proportion reported in a Swedish 
study of 199 LC patients (30). In another Swedish study, 10% of the patients with histological 
features of MC – a majority of them CC patients – did not report chronic watery diarrhoea 
(153); other studies have reported similar findings (154, 155). 
In our study, the main MC symptom was watery diarrhoea with a stool frequency of four to 
nine per day, often associated with abdominal pain, nocturnal diarrhoea, urgency and weight-
loss, which is already described in earlier studies (60, 156). We confirmed that the symptoms 
of LC and CC are indistinguishable, as found in several previous studies (33, 89). However, 
we showed that the frequency of symptoms differed between the subtypes. There were small 
but significantly higher occurrences of chronic diarrhoea, watery diarrhoea and nocturnal 
diarrhoea in CC patients than in LC patients; this has been described in few previous studies 
as well (90, 91, 127). 
5.1.3   Associated  diseases  
Autoimmune diseases are associated with MC in up to 50% of the patients (37). The overall 
prevalence of coeliac disease in Sweden is 3% (157), and 3–23% in the MC population (15, 
158, 159). A large population study showed a strong association between MC and coeliac 
disease with disease concomitance being 50 times higher than expected in general population 
(15). In our study, we reported the prevalence of coeliac disease of 6%, higher in LC (6.9%) 
than in CC (4.9%) (NS). These figures fit well with the pooled results of 14 studies showing 
coeliac disease in 7% of LC and 5% of CC patients (33). There have been reports of MC 
progressing to IBD and vice versa (90, 160-164) and 2.1% of our MC patients had UC or CD. 
This is in the same range found in a previous Swedish study, 2.5% (28). At the same time, a 
recent large study concluded that there is no increased risk of developing IBD, only 2 of 547 
cases established the diagnosis of UC or CD prior to the diagnosis of MC (165). In our study, 
the majority had established the IBD diagnosis prior to the MC diagnoses, and this may 
complicate the histological distinction between these diagnoses. MC biopsies can contain 
neutrophils with active cryptitis (41), although acute inflammation should not dominate the 
inflammatory infiltrate. 
5.1.4   Endoscopic  findings  
Despite the name microscopic colitis, the colonic mucosa is not always normal. Subtle or 
nonspecific mucosal changes such as oedema, erythema, abnormal vessel patterns, nodular 
surface, linear tears and scratches, have been observed (101, 166, 167). 
Subtle macroscopic mucosal changes in the colon have been described in other Swedish 
studies (28, 30), and such findings were seen in 37% of CC and 26% of LC patients; 
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however, we found a significant difference between the subtypes. Our study also reports low 
rates of neoplastic lesions at the index colonoscopy, despite the patients’ high age, and this is 
significantly lower than in the previous population based on Forsberg et al.’s endoscopic 
study (139). This is supported by two studies showing that MC was negatively associated 
with the risk of colorectal adenomas, and in one study even including earlier colonoscopies 
(133, 134). In our study, we lack information on earlier colonoscopies and on 
NSAIDs/aspirin use which can prevent colorectal neoplasia (168). 
5.1.5   Clinical  and  endoscopic  follow-­up    
The long-term prognosis of MC is generally good, but most studies conducted to-date 
examine small sample sizes or are only limited in sample follow-ups. 
In our data, 64% of the MC patients were in clinical remission at the last clinical follow-up at 
a mean time of 2.9 years after diagnosis. Two studies with much smaller sample sizes but a 
mean follow-up time of 6–9 years showed that only a minority of MC patients have 
symptoms at follow-up (125, 126), and other studies showed remission rates 48-70% (91, 93, 
137, 169, 170). We could also show that the histological remission rate was 44% at the first 
follow-up colonoscopy and the histological remission rate might even be higher in our study 
since most asymptomatic patients did not undergo a follow-up colonoscopy. Comparative 
histological follow-up studies in MC are scarce (110, 111). 
Our data, which studied the two MC subtypes in the same large, well-defined urban cohort, 
found that clinical and histological remission over time were better in LC patients who 
needed less treatment – specifically, lower steroid use – than CC patients. LC seems to be a 
milder disease with better prognosis than CC, as has been concluded in a few studies (113, 
127). With regard to LC, one study showed that 80% of patients had no diarrhoea and showed 
normalised mucosal histology follow-up at a mean of three years (128), while another 
showed 73% histological remission already after six weeks in LC cases (113). One study 
showed that 63% of LC patients described the course of LC as one single outbreak (30), 
compared to 2% in CC cases (28). In case of CC, clinical studies showed relapse in 30% of 
patients, while prospective, placebo-controlled trials reported an 80% relapse rate (91, 117). 
Changes in histological phenotype over time were not uncommon. According to our data, 
12% changed subtype during follow-up. Four previous Swedish studies reported a total of 23 
conversion cases between the subtypes, with a majority (n=19) shifting from LC to CC (30, 
35, 93, 171). If this is true conversions between subtypes or rather reflects diagnostic 
difficulties or natural fluctuations of same disease is controversial. 
5.1.6   Genetics  
The aetiology of MC is still unknown, but the high frequency of autoimmune diseases, the 
high frequency among women, familial occurrence and the response to corticosteroid therapy 
support an autoimmune origin. Earlier genetic studies, though are sparse, small and 
underpowered, have shown an association between HLA-DQ and MC, as well as an 
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association between MC and TNFa, metalloproteinase-9, IL-6 and serotonin transporter 
promoter genes polymorphisms (47, 48, 50-53). 
No large-scale genetic study of MC has been done before to determine whether genetics have 
a role in MC and, if so, identify the genetic variants associated with MC. We genotyped 
around 300 CC patients and 42 markers gave significant association signals, all in the HLA 
region on chromosome 6. This supports the idea of a genetic role in CC and a HLA related 
immune mechanism may be involved in CC pathogenesis. The small sample size is a major 
limitation in our study, limiting the statistical power and ability to detect other associations. 
However, Roda et al. recently conducted a study in the United States, which was in parallel to 
us and which appeared only in abstract form. The study examined a discovery cohort of 
similar size (N=295), used the same methodology (Immunochip) (172), and reported findings 
similar to ours. Roda et al. that same year, conducted a genome-wide association study 
(GWAS) of 450 CC patients and the preliminary results showed that 10 loci were 
significantly associated with CC, and that the most significant association signal was near 
HLA-DQ (173). 
MC and coeliac disease are associated. The strongest genetic risk factor for coeliac disease is 
linked to the HLA-gene encoding HLA-DQ2 (146). In our study, in which patients with 
history of diagnosis of coeliac disease were excluded and the majority of the study population 
were screened for coeliac disease, we confirmed the association between CC and DQ2.5. The 
results suggest that they have a genetic overlap and similar pathogenesis mechanisms. 
A similar genetic study using Immunochip in LC patients did not show any association with 
the HLA genotype (174). However, the study cohort was small, and it is known in general 
that LC is a heterogeneous disease where drugs, gastrointestinal infections or another 
gastrointestinal disease can cause lymphocyte infiltration in colonic mucosa epithelium (175). 
A small study also shows an increase of HLA A1 in LC patients (49). Still, this suggests that 
the LC and CC may have different pathogeneses and thus may be two different diseases, 
which aligns with our results and other studies showing that LC has a more benign clinical 
presentation and a better prognosis, and that concomitant autoimmune disease is less 
common in LC patients than CC patients (30, 91, 127). However, as said before, this remains 
controversial. 
Conversions between MC and IBD have been observed in our descriptive studies (I and II), 
as well as in other studies (61, 171). We studied CC Immunochip associations signals at >25 
000  IBD risk SNPs (176) and found concordant risk suggesting a genetic overlap between 
CC and IBD, which is supported by the findings of the genome-wide association study of CC 
(173). 
5.1.7   Endoscopic  diagnosis  
Grooves deep enough to retain barium and give a radiographic pattern were found in the 
surface of the normal colon. These innominate grooves of colonic mucosa were first 
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described radiologically by using the air double-contrast method (177). Later, they were seen 
during colonoscopy, though only by using the dye spray method (144). Only two MC case 
reports described their appearance at colonoscopy with indigo carmine, showing uneven 
surface texture in CC patients (108, 109). A retrospective study of colonoscopies without 
chromoendoscopy in patients with diarrhoea reported finding mosaic patterns in MC patients 
(178). Our study was a case series where indigo carmine staining was used at colonoscopy as 
a diagnostic tool for MC in 13 patients. We reported subtle mucosal abnormalities shown in 
patients with MC using chromoendoscopy. We recognised that a mosaic mucosal pattern was 
seen in all LC patients and in half of CC patients, and a nodular mucosal pattern was 
observed only in CC patients, and uneven surface in both subtypes; however, these 
appearances seem to overlap with one another. 
In addition, our study showed that chromoendoscopy revealed continuous mucosal changes 
in 13 MC cases. The continuous changes were also seen in the histopathology. This contrast 
previous studies that have reported patchy histological distribution (179, 180). In three CC 
patients, the correlation between the chromoendoscopy findings and the histopathology in the 
rectosigmoid was poor and may illustrate a limitation of this method in the left colon. 
Moreover, inflammatory changes of CC cases are less apparent in the left colon (179). 
However, studies on biopsies taken from the rectosigmoid showed that the diagnosis of MC 
could be confirmed in as much as 70–95% of cases (90, 181, 182). The data conflicts, and 
until further evidence is available, colonic biopsies from both right and left colon should 
remain the golden standard (183). 
Only 3 of 13 MC patients had no mucosal abnormalities detected by white light endoscopy. 
This contrast the common belief, but these changes were considered as minor and are often 
overlooked in routine endoscopic examinations. Endoscopist bias must also be considered, as 
from the onset, the endoscopists knew that the majority of cases had previously been 
diagnosed with MC.  
 30 
 
6   CONCLUSIONS  
 
•   LC and CC are similar but not identical. 
 
•   LC tends to occur earlier in life, and it has a milder clinical presentation and a better 
prognosis. 
 
•   Colonic mucosa in MC is not always normal, despite the name ‘microscopic’. 
 
•   There is a strong association between MC and coeliac disease. 
 
•   Conversions between MC and UC/CD and between LC and CC over time are not 
uncommon. 
 
•   Specific HLA alleles are associated with CC, which indicates an autoimmunity. 
 
•   Chromoendoscopy may improve detection of macroscopic lesions in MC patients and 
could help select patients for biopsy, as well as direct the biopsies. 
 
•   LC and CC might be two different entities, but further large prospective studies are 
needed to clarify the clinical and histological courses of the two subtypes. Further 
GWAS-based MC studies are warranted to detect genetic differences between the 
subtypes. 
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